Johnson & Johnson (JNJ) has been a quiet yet impressive performer in the healthcare sector, and it's easy to see why long-term investors are taking notice. With a landmark $100 billion revenue year in the making and 11 Innovative Medicine brands growing at double digits, JNJ is setting itself up for a bright future. In this article, I'll delve into the key factors driving JNJ's success, explore its pipeline, and discuss why it's a compelling investment opportunity. I'll also provide my personal perspective on the company's prospects and compare it to its peers, Merck and Pfizer.
A Pipeline Story
One of the most exciting aspects of JNJ is its robust pipeline. The company has a diverse range of innovative medicines in development, with a particular focus on psoriasis and psoriatic arthritis. The first oral IL-23 for psoriasis, ICOTYDE, has already shown impressive traction with 1,500 patient prescriptions in the first weeks post-launch. This is a significant development, as CEO Joaquin Duato has described ICOTYDE as "one of our largest products ever." Additionally, TREMFYA is tracking to peak sales above $10 billion, with RYBREVANT/LAZCLUZE growing 82.7% and CARVYKTI up 62.1%. These strong performances are a testament to JNJ's ability to develop and commercialize innovative therapies.
A Strong Foundation
JNJ's strong foundation is another key factor in its success. The company has a 64-year fortress of dividend payments, which provides a steady stream of income for investors. Moreover, the DePuy Synthes separation has removed an anchor from reported growth, allowing JNJ to focus on its core strengths. This strategic move has helped JNJ to exit its litigation and STELARA overhang, which is a significant positive for the company.
A Compelling Investment Opportunity
JNJ is a compelling investment opportunity for several reasons. Firstly, the company is exiting its litigation and STELARA overhang, which is a significant positive for the company. Secondly, JNJ's pipeline is derisked, with a diverse range of innovative medicines in development. Lastly, JNJ's strong foundation, including its dividend payments and strategic moves, makes it a stable and reliable investment. In my opinion, JNJ is well-positioned to deliver strong returns for investors in the coming years.
A Comparison to Peers
JNJ is a strong performer in the healthcare sector, but how does it compare to its peers, Merck and Pfizer? Merck is the cleanest comparison on oncology franchise concentration, with a 2026 EPS guide of $5.04 to $5.16. However, JNJ's 28 billion-dollar brands do not carry the same concentrated patent-cliff risk as Merck's KEYTRUDA. Pfizer, on the other hand, trades at a trailing P/E of 18 with a 7.09% dividend yield, reflecting COVID-cliff and Eliquis loss-of-exclusivity concerns. JNJ, in contrast, trades at a forward P/E of 22 with a 2.01% yield. JNJ is delivering accelerating 9.91% revenue growth, while Pfizer's 2026 revenue is guided flat. In my opinion, JNJ's strong performance and innovative pipeline make it a more compelling investment opportunity than its peers.
A Bright Future
In conclusion, JNJ is a healthcare giant that is well-positioned to deliver strong returns for investors in the coming years. With a landmark $100 billion revenue year in the making and a robust pipeline of innovative medicines, JNJ is a compelling investment opportunity. Moreover, JNJ's strong foundation and strategic moves make it a stable and reliable investment. In my opinion, JNJ is a buy with 90% confidence, and I believe it has the potential to deliver significant returns for investors in the coming years.
